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Abstract
The phytotherapeutic protein stem bromelain (SBM) is used as an anti-obesity alternative medicine. We show at the cellular
level that SBM irreversibly inhibits 3T3-L1 adipocyte differentiation by reducing adipogenic gene expression and induces
apoptosis and lipolysis in mature adipocytes. At the molecular level, SBM suppressed adipogenesis by downregulating C/
EBPa and PPARc independent of C/EBPb gene expression. Moreover, mRNA levels of adipocyte fatty acid-binding protein
(ap2), fatty acid synthase (FAS), lipoprotein lipase (LPL), CD36, and acetyl-CoA carboxylase (ACC) were also downregulated
by SBM. Additionally, SBM reduced adiponectin expression and secretion. SBM’s ability to repress PPARc expression seems
to stem from its ability to inhibit Akt and augment the TNFa pathway. The Akt–TSC2–mTORC1 pathway has recently been
described for PPARc expression in adipocytes. In our experiments, TNFa upregulation compromised cell viability of mature
adipocytes (via apoptosis) and induced lipolysis. Lipolytic response was evident by downregulation of anti-lipolytic genes
perilipin, phosphodiestersae-3B (PDE3B), and GTP binding protein Gia1, as well as sustained expression of hormone sensitive
lipase (HSL). These data indicate that SBM, together with all-trans retinoic-acid (atRA), may be a potent modulator of obesity
by repressing the PPARc-regulated adipogenesis pathway at all stages and by augmenting TNFa-induced lipolysis and
apoptosis in mature adipocytes.
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Introduction
Adipose tissue is crucial for energy storage and lipid homeostasis
[1,2,3], but an imbalance between energy intake and expenditure
leads to obesity, which is a major risk factor for many chronic
diseases and metabolic disorders such as type 2 diabetes,
hypertension, hyperlipidemia, and arteriosclerosis [4]. Under-
standing the pathophysiology of obesity and finding treatment
regimens are emerging areas of research. The preadipose 3T3
clonal cell line, 3T3-L1 [5], is a convenient cell culture model for
both investigation of the program of adipogensis and determina-
tion of factors that regulate the physiology of the mature
adipocyte. Quiescent cells can be induced to differentiate by the
addition of various hormones or drugs in the presence of
adipogenic factors that are in fetal bovine serum.
Adipose tissue mass is determined by processes governing
adipocyte size and number [6]. The size of adipocytes increases
because of increased storage of triacylglycerols from dietary
sources or endogenous lipogenic pathways. Adipocyte number
increases as a result of increased proliferation and differentiation
[7]. Early in the adipogenic differentiation program preadipocytes
undergo mitotic clonal expansion (MCE): a process that differs
from proliferation of nonconfluent adipocytes and is essential for
adipocyte differentiation [8]. MCE is accompanied by induction of
CCAAT/enhancer-binding protein (C/EBP) b and C/EBPd.
During mid-phase adipocyte differentiation, the expression of
CEBPa and PPARc, which are both antimitotic, occurs as the cells
exit the cell cycle. These proteins are thought to be terminating
MCE [9,10]. C/EBPa and PPARc then coordinately drive
expression of adipocyte-specific genes such as adipocyte fatty
acid-binding protein 2 (aP2), fatty acid synthase (FAS), acetyl-CoA
carboxylase (ACC), lipoprotein lipase (LPL), and cluster of
differentiation (CD) 36, many of which characterize the final
stages of differentiation [11]. The cAMP/glucocorticoid-triggered
C/EBPb pathway leading to PPARc expression is now understood
to be distinct from insulin stimulated Akt–tuberous sclerosis
complex (TSC2)–mammalian target of rapamycin (mTORC)
pathways leading to PPARc expression [11,12]. Decreases in
adipose tissue mass may involve the loss of lipids through lipolysis
and the loss of mature fat cells through apoptosis [13].
The clinical importance of herbal drugs and vitamins for
treatment of obesity has received considerable attention
[14,15,16]. These therapies have been variably efficacious on
signaling pathways at early, middle, and late stages of adipocyte
differentiation, and together with several other non-invasive
dietary treatment regimens are desirable for this chronic disease.
A number of herbal (flavonoid) and dietary inhibitors of adipose
differentiation have been identified, including isorhamnetin [17],
(-)-epigallocatechin-3-gallate (EGCG) [18], silibinin [19], retinoic
acid [20], and 1,25(OH)2D3 [21].
Fruits such as papaya and pineapple (Ananas comosus) are also
active constituents of an anti-obesity diet. Stem bromelain (SBM)
[3.4.22.32], a widely accepted phytotherapeutic drug, is a member
of the bromelain family of proteolytic enzymes obtained from A.
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has several other therapeutic effects [23,24,25,26]. In addition, it is
being used efficaciously as an anti-obesity pill (France Vita Natura
Pvt Ltd.). While its anti-metastatic effects and its modulation of
immune cells have been adequately addressed [25,27,28,29], its
mechanism of action on adipocytes, however has not been
addressed or understood. The diverse effects of SBM appear to
depend on its unusual ability to traverse membranes and its
acceptability as an orally administered enzyme with minimal side
effects [24,30,31,32,33]. This has been confirmed by several
Good Clinical Practice (GCP)-conforming clinical studies [26,
33,34,35,36]. Because of its therapeutic use in treatment of
obesity, it is crucial to understand the biological effects of SBM in
the cell milieu.
The objective of this study was to elucidate the molecular
mechanism of SBM modulation of adipogenesis using 3T3-L1
adipocytes as a model system. Interestingly, SBM modulates mid-
and late-stage differentiation, but not MCE (early stage). It does so
by selectively inhibiting the Akt phosphorylation and augmenting
TNFa expression; these actions lead to repression of PPARc and
C/EBPa and their target genes aP2, LPL, FAS, ACC, and CD36,
which are all involved in adipogenesis. The effects of SBM, unlike
those of atRA and 1,25(OH)2D3, are irreversible and can occur
post differentiation via the promotion of key events in apoptosis
and lipolysis. These effects of SBM are dependent on its
proteolytic activity. SBM and atRA treatment together was more
potent in inhibiting adipocyte differentiation than any of the
treatments alone.
Materials and Methods
Cell culture and differentiation
3T3-L1 mouse embryo fibroblasts was procured from cell
repository at national centre for cell science, Pune, India and were
cultured as described elsewhere (29). In brief, preadipocytes were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal calf serum until confluent. All media
contained 1% penicillin–streptomycin (10,000 U/ml) and 1%
(vol/vol) 100 mmol/l pyruvate. Cells were maintained at 37uCi n
a humidified, 5% CO2 atmosphere. For the differentiation of
preadipocytes, two days after confluence, the cells were stimulated
with DMEM containing 10% fetal bovine serum (FBS),
167 nmol/l insulin, 0.5 mmol/l isobutylmethylxanthine, and
1 mmol/l dexamethasone for 2 days. On day 2, the differentiation
medium was replaced with 10% FBS/DMEM containing
167 nmol/l insulin. This medium was repleted every two days.
Preadipocyte and adipocyte were treated with vehicle or test
compounds in relevant media for time points as mentioned in
figure legend. Total cell mass was assessed for different
parameters.
Oil Red O staining
Cells in 6-well/60 mm plates were washed twice with PBS and
fixed for 10 min with 4% paraformaldehyde in PBS (pH 7.4).
Cells were then stained for 30 min with Oil Red O (0.5 g in
100 ml isopropanol) as described by Suryawan and Hu [37]. In
some wells, Oil Red O dye retained in the cell was quantified by
elution into isopropanol, and OD500 was measured.
GPDH activity assay
Cultured cells in 6-well/60 mm plates were treated with vehicle
or test compound (10 mg/ml in PBS) along with differentiation
media. Cells were washed twice with cold phosphate buffered
saline (PBS) and collected by scraping with a cell scraper into
50 mM Tris-HCl (pH 7.5) containing 1 mM EDTA. The
harvested cells were sonicated for 5 sec at 20% amplitude. After
centrifugation at 13,0006g for 5 min at 4uC, the supernatants
were assayed for GPDH activity. GPDH activity was determined
spectrophotometrically by measuring the oxidation of NADH in
the presence of dihydroxyacetone phosphate (DHAP).
Quantification of triglycerides
Triglycerides were quantified by alkaline hydrolysis and
measurement of released glycerol by the Free Glycerol Determi-
nation Kit (Sigma).
MTT assay
Cells were cultured in a 96-well dish. After treatment for 24 h, a
20 ml aliquot of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrao-
lium bromide (MTT, a yellow tetrazole; 5 mg/ml in PBS) was
added to the wells and incubated for 4 h at 37uC. The supernatant
was removed carefully, 200 ml of DMSO was added and mixed,
and the absorbance was read at 563 nm.
Staining with annexin-V and PI
The annexinV-FITC Apoptosis Detection Kit (Calbiochem)
was used to stain cells in annexin binding buffer according to the
manufacturer’s instructions. Cells were analyzed with a BD
FACSCalibur flow cytometer (BD Biosciences). For quantification
of % apoptotic cells, the cells were labeled with annexin V-FITC
and six randomly selected fields were counted for fluorescent cells.
TUNEL assay
Cell cultures were fixed with 4% paraformaldehyde, and in situ
detection of cells with DNA strand breaks was performed by the
terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) method using a Fluorescein FragEL
TM DNA Fragmen-
tation Detection Kit (Calbiochem) according to the manufacturer’s
instructions. Negative controls were performed by substituting Tris
buffered saline (TBS) for the TdT enzyme. Cells labeled with the
Fluorescein-FragEL DNA fragmentation detection kit (Cat No.
QIA39) were analyzed with a BD FACSCalibur flow cytometer
(BD Biosciences).
Assay of DNA fragmentation
After treatment with vehicle or SBM, the cells were scraped and
DNA was isolated as described elsewhere [38]. DNA fragments
thus obtained were electrophoretically separated on a 1% agarose
gel at 100 V for 30 min. The gel was stained with ethidium
bromide and photographed under UV transillumination.
ELISA of adiponectin
Adiponectin concentrations in cell supernatants were measured
by enzyme-linked immunosorbent assay (ELISA). Adiponectin was
captured in multiwall dishes by immobilized antibodies directed
against mouse adiponectin. Captured protein was then detected by
adding a second antibody against mouse adiponectin followed by a
secondary anti-IgG antibody coupled to horseradish peroxidase
(HRP). HRP substrate was added to the wells, and the intensity of
the color change caused by the enzymatic reaction was measured
at 450 nm.
Cell proliferation assay
To assess cell proliferation, [
3H]thymidine incorporation was
measured after induction of differentiation of 3T3-L1 in the
presence of 1 mCi of [
3H]thymidine for 24 h. Briefly, cells were
washed twice with PBS, once with ice-cold 10% TCA, and twice
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h and samples were analyzed by a scintillation counter.
Transactivation assay
The CD36 promoter, containing a PPARc response element with
the sequence 59-AAGTCAGAGGCCA-3’, was cloned into the
pGL3-Basic vector (Promega) by PCR-based cloning using a
forward primer with an MluI restriction site and a reverse primer
with a BglII site(creating a 300 bppromoter with a PPARc response
element) as mentioned elsewhere [39,40]. The mutated PPARc
response element with the sequence 59-AAGTCAGTTTCA-39,f o r
the CD36 promoter reporter was made by QuikChange Multi Site-
Directed Mutagenesis Kit (Stratagene). The transactivation assay
wasperformed using pGL3-CD36promoterplasmidand aninternal
control (Renilla luciferase). Mature adipocytes (control and treated)
were transiently transfected with a total of 500 ng pGL3-CD36
promoterplasmidandaninternalcontrol(Renillaluciferase).Relative
luciferase activity was calculated by comparing the luciferase activity
of the reporter construct with that of the internal control (Renilla
luciferase). Transfection was done using Lipofectamine PLUS
reagent (Invitrogen) according to the manufacturer’s instructions.
Normalized luciferase activities (relative light units; RLU) were
plotted as the average (6 SD) of data from triplicate wells from
different cell culture.
RT PCR
Cells were harvested in 1 ml of Trizol reagent (Invitrogen) and
RNA was extracted according to the manufacturer’s instructions.
cDNA synthesis was performed with the RevertAid First Strand
cDNA Synthesis kit (Fermentas) for RTPCR and RT-qPCR. RT-
qPCR was performed in 96-well plates with the SYBR Green RT-
qPCR kit (Invitrogen). PCR was performed in an iCycler iQ real-
time PCR detection system, and the PCR baseline-subtracted data
were computer generated as described by the manufacturer (Bio-
Rad). 18S rRNA and b-actin were used as reference housekeeping
genes for normalization. Primer details are available as Supporting
information Table S1.
Immunoblot analysis
Antibodies specific for b-actin, p-Akt, Akt, PPARc, adiponectin,
C/EBPa, C/EBPb, and C/EBPd, and all the secondary
antibodies were from Santa Cruz Biotechnology (Santa Cruz,
CA). Western blots were performed as described previously
[28,41].
Reagents
SBM [EC 3.4.22.32] was obtained from Sigma. SBM solutions
of native and catalytic-ally inactive were prepared, dialyzed
extensively and subjected to size exclusion chromatography as
mentioned elsewhere [28,42,43]. MTT assay reagents, Oil Red O,
haematoxylin stain, insulin, b-nicotinamide adenine dinucleotide,
dihydroxyacetone-3-phosphate, triethanolamine, atRA (purity
$98% (HPLC)), 1,25-dihydroxyvitamin D3 (1,25(OH)2D3; vita-
min D) (purity $99% (HPLC)), dexamethasone, and 3-isobutyl-1-
methylxanthine were obtained from Calbiochem. DMEM, Trizol,
fetal bovine serum, and penicillin–streptomycin were purchased
from Invitrogen. Fetal calf serum was purchased from Hyclone.
All chemicals not listed here were of analytical grade.
Statistics
Results are expressed as the mean 6 SD unless otherwise
mentioned. SigmaPlot (SyStat Software) and SPSS (IBM) were
used for statistical analysis. All statistical data were from averages
of three or more independent experiments. Two-tailed Student t
test was performed to obtain P values. Statistical significance was
established at * P,0.01, ** P,0.05. The efficiency of PCR
amplification for each gene was calculated by the standard curve
method (E=10
2(1/log slope)). Gene expression was quantified by the
comparative cycle threshold method (28), using 18S mRNA as an
endogenous control. For relative mRNA abundance of C/EBPa
C/EBPb, C/EBPd, and PPARc, five different cell culture of SBM-
inhibited adipocyte differentiation were considered in the study,
and expression was calculated relative to control differentiated
adipocytes after normalization to 18S rRNA.
Results
SBM inhibits 3T3-L1 adipocyte differentiation
To investigate the effect of SBM on adipocyte differentiation, we
first looked at the accumulation of intracellular lipids. Confluent
(day 0) 3T3-L1 pre-adipocytes treated with the inducing agents
dexamethasone (Dex) and isobutyl methyl xanthine (IBMX) in the
presence of fetal bovine serum and insulin, accumulate prominent
lipid droplets as early as 4 days, however are more pronounced at
day 8, and can be stained with Oil Red O. Treatment of cells with
50 mg/ml proteolytically active SBM during this time suppressed
the number of colonies that stained for lipid (Figure 1A). This effect
was30%morepronouncedthantheinhibitioncausedbyatRA,and
it was not seen with the application of inactive SBM. While lower
concentrations of active SBM were also effective in inhibiting
differentiation, a saturating effect was seen at 50 mg/ml (Figure 1B).
Short treatments with SBM (as short as 6 h) followed by a change of
medium suppressed the adipocyte phenotype as effectively as when
the drug was present continuously. Thisresult, however, may reflect
the difficulty of removing SBM from the cultures, due to its
membrane-traversing ability [28,32], and a minimal time require-
ment for SBM action cannot be assessed. For practical purposes,
SBM was added to cultures during the treatment with Dex and
IBMX, and it was maintained in the cultures when cells were
switched to medium with fetal bovine serum and insulin alone.
To further characterize the extent of suppression of differenti-
ation by SBM, estimates of cellular triglyceride (TG) content and
glycerol-3-phosphate dehydrogenase (GPDH) activity were made,
as these measures have been shown in most cases to correlate well
with differentiation (Figure 1C and D). In both cases, values from
SBM-treated dishes were ,25% of control (untreated) values (TG,
2263%; GPDH, 2867%). The results from the GPDH assays
were more variable and in some experiments appeared higher
than expected, as compared to Oil Red O staining of replicate
dishes. This could be because of the saturating activity of GPDH
in cells that have been able to escape SBM-mediated inhibition of
adipocyte cell differentiation.
We then investigated mRNA expression of the key genes C/
EBPa, C/EBPb, C/EBPd, and PPARc, which are involved in
early- and mid-phase differentiation of adipocytes (Figure 1E, left
panel). As expected, SBM reduced the mRNA level of C/EBPa
and PPARc, but interestingly, it did not affect the expression of C/
EBPb or C/EBPd. Protein expression of these adipocyte markers,
as measured by immunoblot, correlated with peak mRNA
concentrations (Figure 1E, right panel). Relative expression
(2
-(DDCt)) of mRNA as calculated from RT-qPCR corroborates
the above (Figure 1F).
SBM selectively inhibits mid- and late-phase
adipogenesis
We next examined the effect of SBM (50 mg/ml) on early-, mid-,
and late-phase differentiation. Early in adipogenesis, differentiation
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rounds of division (MCE), which is a prerequisite for differentiation
into adipocytes. The number of preadipocytes increased almost
twofold in 24 h after the addition of differentiation medium, in
accordance with previous reports [44]. Interestingly, SBM had no
effect on cell number or thymidine incorporation after induction of
differentiation (Figure 2A and B). This result was expected, as SBM
did not affect the expression of C/EBPb or C/EBPd, which are
known to modulate MCE.
We then investigated mRNA levels of C/EBPa, C/EBPb,C /
EBPd, and PPARc, as well as aP2, FAS, LPL, and CD36. The
latter proteins are markers of the final stages of adipocyte
differentiation. They are target genes of C/EBPa and/or PPARc.
(Figure 2C). As expected, expression of C/EBPb and C/EBPd was
Figure 1. SBM inhibits adipocyte differentiation of 3T3-L1 cells. Two-day postconfluent 3T3-L1 preadipocytes (day 0) were treated with the
indicated concentrations of SBM and was repleted every 2 days along with the relevant media cocktail upto day 8. Cells treated with 1X PBS were
used as controls. The assays were performed on day 8. (A) Intracellular lipids were stained with Oil Red O. (B) Absorbance was spectrophotometrically
determined at 500 nm after Oil Red O staining. (C) Triglyceride (TG) content (per mg protein) was measured with a triglyceride estimation kit (Sigma).
(D) Glycerol-3-phosphate dehydrogenase (GPDH) activity (U/mg protein) was measured using a GPDH activity assay. (E) mRNA (RT PCR) and protein
expression (western blot) of the adipogenic transcription factors C/EBPa, C/EBPb, C/EBP-d, and PPARc. Results were expressed relative to untreated
cells after normalization to TATA binding protein (TBP) and b Actin. (F) mRNA abundance of C/EBPa, C/EBPb, C/EBPd, and PPARc in SBM-treated
adipocytes relative to control differentiated adipocytes after normalization to 18S rRNA. Five biological replicates of SBM-treated adipocytes were
tested. The results were confirmed by three independent experiments, which were each conducted in triplicate. Data are expressed as the mean 6
SD. *P,0.01, **P,0.05 vs. controls.
doi:10.1371/journal.pone.0030831.g001
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by SBM. The expression of C/EBPa and PPARc, however, was
significantly reduced by SBM treatment, especially at late time
points. Because SBM downregulated the expression of C/EBPa
and PPARc, we speculated that the expression of their target genes
might also be downregulated. Indeed, under SBM treatment, the
mRNA levels of aP2, FAS, LPL, and CD36 were notably reduced.
Effect of SBM on 3T3-L1 cell viability and survival
To determine whether SBM treatment affects cell viability and
survival in 3T3-L1 preadipocytes and mature adipocytes, we
performed an MTT assay, annexin–propidium iodide (PI)
staining, a TUNEL, and a DNA fragmentation assay. Interest-
ingly, while the MTT assay revealed only subtle changes in
preadipocytes viability at all tested concentration of SBM, the
viability of mature adipocytes at higher concentrations of SBM
(100 mg/ml) was significantly reduced (Figure 3A and B). To
determine whether the reduction in cell number was caused by
apoptosis, annexin–PI staining was performed (Figure 3C). The
annexin-PI staining combination assay detected apoptotic cell
membrane phosphatidyl serine (PS) externalization and served as a
measure of adipocyte viability. Whereas no significant increase in
apoptosis was observed at 10 mg/ml and only a slight increase was
observed at 50 mg/ml SBM concentration, a significant proportion
of mature adipocytes underwent apoptosis at an SBM concentra-
tion of 100 mg/ml. Although annexin-PI staining is considered
quantitative, it requires the segregation of cells for FACS analysis,
and in that process may undercount some cells because of
associated annexin V leaching. To address this issue, annexin V
imaging was performed; it provided similar results but a more
absolute quantitation (Figure 3D). To further investigate whether
SBM-induced apopototic cells underwent DNA damage, we
performed a TUNEL assay, which clearly showed increased
labeling in SBM-treated cells (100 mg/ml SBM) compared to
untreated cells (Figure 3E). Cells that stained positively in the
TUNEL assay also showed DNA fragmentation with DAPI
Figure 2. SBM does not inhibit mitotic clonal expansion. (A) Differentiation of 3T3-L1 cells was induced and cell number was counted in
control and SBM-treated cells using a hemacytometer 24 h after induction. (B) Effect of SBM on DNA synthesis was monitored by [
3H]thymidine
incorporation after induction of differentiation of 3T3-L1 in the presence of [
3H]thymidine for 24 h. Incorporation of [
3H]thymidine into newly
synthesized DNA was quantitated with a scintillation counter. (C) mRNA expression of adipogenic transcription factors C/EBPa, C/EBPb, C/EBPd,
PPARc, CD36, LPL, aP2 and FAS after 1, 4, and 8 days of differentiation in control and SBM-treated cells. Results were expressed relative to untreated
cells after normalization to 18S rRNA. Total cell mass was assessed for different parameters. Data are expressed as the mean 6 SD. *P,0.01, **P,0.05
vs. controls. The results were verified by four repetitions of the experiments, each of which was conducted in triplicate. Black bars = 2SBM, gray bars
= +SBM.
doi:10.1371/journal.pone.0030831.g002
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30831Figure 3. SBM induces apoptosis in mature adipocytes. Effect of SBM on the viability of, (A) 3T3L-1 preadipocyte and (B) mature adipocytes (8
days), as determined by MTT assay. Values are expressed as a percentage survival as compared to control after a 24 h incubation. (C) SBM-induced
apoptosis in mature adipocytes evaluated by annexin-V/PI-FACS analysis. Annexin: FL1-H; PI: FL2-H. (D) Quantification of annexin V positive cells by
imaging. At least 500 cells were analyzed. (E) Control (vehicle-treated) and SBM-treated mature adipocytes were either fixed and stained with DAPI
and analyzed by fluorescence microscopy, or analyzed for DNA fragmentation by TUNEL. Cells labeled with the Fluorescein-FragEL were analysed by
FACS shown, cell only (green) and cell treated with 100 mg/ml SBM (red), 1 mg/ml Vinblastine (purple) (left panel). Quantification of SBM-induced
apoptosis in mature adipocytes by TUNEL assay (right panel). Micrographs of control and SBM-treated cells stained with DAPI are shown (bottom
panel). (F) Demonstration of apoptosis by gel electrophoresis. Mature adipocytes were incubated with SBM at various concentrations for 24 h. Lane 1,
Modulation of Adipogenesis by Stem Bromelain
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supported by a DNA fragmentation experiment in which the
genomic DNA of mature preadipocytes treated with SBM or
vehicle was electrophoretically separated by agarose gel electro-
phoresis. DNA fragments obtained at 100 mg/ml SBM can be seen
in the gel as a typical ladder migration (Figure 3F).
SBM affects lipolysis by downregulating perilipin
SBM’s effect on differentiated adipocytes (8 days) was
monitored by Oil Red O staining (Figure 4A). A significant
reduction in Oil Red O content was observed in 10–100 mg/ml
SBM, suggesting a role for SBM in lipolysis. Free glycerol release
was measured to get an estimate of lipolysis, which was
significantly higher in SBM treated adipocytes (Figure 4B) at as
low as 10 mg/ml and higher SBM concentrations. SBM’s effect on
lipolysis was assessed by measuring the expression levels of
perilipin, phosphodiesterase-3B (PDE3B), GTP binding protein
(Gia1), hormone-sensitive lipase (HSL), and tumor necrosis factor
a (TNF-a) upon SBM treatment of mature adipocytes (post
differentiation, 8 days) by real-time PCR. Treatment with SBM
downregulated expression of perilipin, PDE3B, and Gia1, and
upregulated the expression of TNF-a (and secretion; data not
shown), but no significant changes were observed in expression of
HSL (Figure 4C). SBM was also able to downregulate adiponectin
expression and secretion (Figure 4D).
SBM inhibits the expression of PPARc by modulation of
the Akt pathway
Because SBM does not modulate the transient cAMP/
glucocorticoid-triggered CEBPb pathways that contribute to early
PPARc expression [11], we suspected that SBM was involved in
inhibition of PPARc via an alternative mechanistic pathway
triggered by Akt [12]. SBM treatment abrogates Akt phosphor-
ylation in a pattern that correlates with PPARc expression and
without affecting Akt protein expression (Figure 5A). Akt
phosphorylation regulates diverse biological processes [45], many
of which could contribute to Akt’s role in driving adipocyte
differentiation. Indeed, the Akt–TSC2–mTORC1 pathway has
been shown to regulate adipocyte differentiation by controlling
PPARc expression [12]. SBM upregulates TNFa in mature
adipocytes, leading to repression of PPARc expression. It seems
that inhibiting the Akt pathway and increasing TNFa expression
may contribute to PPARc repression. To further explore SBM
modulation of PPARc expression, we measured activation of a
CD36 promoter reporter containing a PPAR response element.
While significant activation of the CD36 promoter reporter was
observed for control mature adipocytes (as monitored by luciferase
activity), CD36 promoter activity was completely lost in the SBM-
treated cells (Figure 5B). These effects were specific to PPARc
activity as CD36 promoter with mutated PPARcRE failed to show
responsiveness to all conditions tested (data not shown).
SBM is an irreversible inhibitor of adipocyte
differentiation that is more potent than atRA and
1,25(OH)2D3
We then investigated SBM’s ability to inhibit adipocyte
differentitation vis-a `-vis vitamins that have been recommended
for obesity disorder: atRA (the acid form of vitamin A) and
1,25(OH)2D3 (vitamin D). We also investigated the reversibility of
SBM’s effect on adipocyte differentiation. SBM, atRA,
1,25(OH)2D3, or combinations of the three were added to the
differentiation medium of adipocytes at days 0–4 and then
removed by changing to fresh SBM-free differentiation medium.
As measured by TG content, SBM was a more potent inhibitor of
adipocyte differentiation (Figure 5C and D). Furthermore, 3T3-L1
cells failed to differentiate into adipocytes after the change to fresh
SBM-free differentiation medium, thus indicating that the
inhibition of adipogenesis by SBM, unlike inhibition by atRA or
1,25(OH)2D3, is irreversible. SBM and atRA treatment together
inhibited adipocyte differentiation more effectively than either
alone (Figure 5C). Comparison of the effect of SBM, atRA, or
1,25(OH)2D3 treatments in differentiated adipocytes (at 8 days),
indicated that only SBM was effective at reducing the TG content
(Figure 5D). This result suggests that not only is SBM-inhibited
differentiation irreversible, but SBM is also a more effective
inhibitor of adipocyte differentiation after the differentiation is
initiated. The time frame during which atRA or 1,25(OH)2D3 can
inhibit adipocyte differentiation is limited to the period immedi-
ately following induction of differentiation with hormonal agents.
Discussion
Because of SBM’s therapeutic utility as anti-obesity alternative
medicine, it is crucial to understand its biological effects in the cell
milieu. In this study, we evaluated the effects of SBM on
adipogenesis in mouse 3T3-L1 cells. Our results demonstrate that
SBM irreversibly inhibits 3T3-L1 adipocyte differentiation by
reducing adipogenic gene expression and that it induces apoptosis
and lipolysis in mature adipocytes.
At the molecular level, adipogenesis is regulated by a complex
transcriptional cascade that involves the sequential activation of
C/EBPs and PPARc [46]. C/EBPb and C/EBPd are rapidly and
transiently expressed after the hormonal induction of differentia-
tion cocktail, and C/EBPb is required for MCE in the immediate
early stages of adipocyte differentiation [47]. These temporally
expressed transcription factors are induced and activated by
cAMP and glucocorticoids and act synergistically to induce the
expression of C/EBPa and PPARc, the master adipogenic
transcription regulators [11,48]. C/EBPa and PPARc, in turn,
promote terminal differentiation by activating the transcription of
the battery of genes involved in creating and maintaining the
adipocyte phenotype. Our results indicate that exposing 3T3-L1
preadipocytes to SBM during adipogenesis reduces the level of C/
EBPa and PPARc mRNA, but that it does not affect the
expression of C/EBPb and C/EBPd (Figure 1E and F). Therefore,
SBM suppression of the upregulation of C/EBPa and PPARc
occurs independently of C/EBPb gene expression. Recent studies
of 1,25(OH)2D3, isorhamnetin (a flavonoid from seabuckthorn),
and 18-alpha-glycyrrhetinic acid (AGA) showed that they reduced
the level of C/EBPa and PPARc mRNA, but did not affect the
expression of C/EBPb [17,21,49]. Conversely, gelsolin (an actin
regulatory protein) and phloretin (a flavonoid in apples) have been
shown to promote adipocyte differentiation by upregulation of C/
EBPa and PPARc without affecting the expression of upstream
regulators C/EBPb and C/EBPd [50,51]. These results are clearly
suggestive of alternative and independent pathways leading to
activation and repression of PPARc. Recently, the Akt–TSC2–
mTORC1 pathway has been shown to stimulate PPARc
expression and adipogenesis [12]. In our study, SBM was able
DNA marker; lane 2, vehicle; lane 7, 1mM vinblastine positive control. Data are expressed as the mean 6 SD. *P,0.01, **P,0.05 vs. controls. Results
were verified by three repetitions of the experiments, which were each conducted in triplicate.
doi:10.1371/journal.pone.0030831.g003
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CD36, and ACC (Figure 2C). Additionally, SBM reduced
adiponectin expression and secretion, an effect that may
contribute to decreased adipocyte differentiation. Interestingly,
SBM seems to reduce Akt phosphorylation in adipocytes. SBM has
been shown previously to reduce Akt phosphorylation in many
other cell lines such as fibroblast, epidermoid carcinoma,
melanoma, and skin papilloma [28,29,52]. Overall, the findings
Figure 4. Increased expression of TNF-a-induces lipolysis in mature adipocytes upon SBM treatment. (A) SBM-treated (24 h, at 0, 10 and
50 mg/ml) mature adipocytes (8 days) were stained for intracellular lipids with Oil Red O. Retention of Oil Red O within cells was quantitated. (B)
Glycerol release into the medium was measured in adipocyte treated with SBM (24 h, at 0, 10 and 50 mg/ml). (C) mRNA expression of the lipolysis-
associated target genes perilipin, HSL, PDE3B, Gia1, TNFa, and PPARc. (D) mRNA expression and secretion of adiponectin. mRNA expression was
calculated relative to untreated mature adipocytes after normalization to 18S rRNA. Adiponectin protein in the media was measured by ELISA after
treatment for 24 hrs at 0, 10 and 50 mg/ml SBM. Data are expressed as the mean 6 SD. *P,0.01 vs. controls. The results were verified by three
repetitions of the experiments, which were each conducted in triplicate. ‘‘2 SBM’’ = cells treated with vehicle, ‘‘+ SBM’’ = cells treated with 50 mg/ml
SBM.
doi:10.1371/journal.pone.0030831.g004
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inhibitory effect of SBM on adipocyte differentiation.
In many cells, including adipocytes, the Akt signaling cascade
leading to NFkB activation is an important signal for cell survival
[53]. Because SBM treatment reduces Akt phosphorylation
without reducing Akt protein, we investigated adipocyte viability
by MTT assay. SBM significantly reduced the viability of mature
adipocytes but not preadipocytes (Figure 3A and B), which is
understandable, as terminally differentiated lineages have more
defined signaling and have distinct signatures [11]. Interestingly,
SBM induced TNFa expression in mature adipocytes (Figure 4).
SBM induction of TNFa has been reported previously in
mononuclear cells [54,55]. The reduction in adipocyte viability
was most apparent at an SBM concentration of 100 mg/ml and is
due to apoptosis but not necrosis, as apparent by annexin–PI
staining, TUNEL assay, and DNA fragmentation assay
(Figure 3C–F). Adipocyte apoptosis is an important mechanism
for regulating adipocyte cell number, and its regulation is
important in obesity-combating strategies [56]. SBM-induced
apoptosis could be implicated in SBM’s ability to block Akt
signaling (Figure 5A) and induce TNFa expression (Figure 4C).
TNFa-induced apoptosis involves binding to TNF receptor 1,
which results in recruitment of TNF receptor-associated death
domain (TRADD) and activation of the cascade of caspases that
leads to cell death and phagocytosis by macrophages [57]. The
TNFa pathway in adipocytes is also known for selective deletion of
adipocytes but not preadipocytes [58], which can be ascribed to
SBM’s ability to selectively induce adipocyte but not preadipocyte
apoptosis. These effects were similar even for longer time frames
tested (data not shown). TNFa can also suppress expression and
Figure 5. SBM is a potent and irreversible inhibitor of adipocyte differentiation. (A) SBM represses PPARc by modulating the Akt pathway.
Western blot of pAkt, Akt, and PPARc in control and SBM-modulated differentiation. b-actin levels are shown as a loading control. Similar results were
obtained for mature adipocytes (data not shown). (B) Estimate of PPARc activity, as monitored by transfection of CD36 promoter luciferase reporter in
mature adipocytes after 12 h of treatment with SBM. Cells were then harvested and lysed 12 h after transfection (24 h treatment with SBM).
Luciferase activity is expressed as relative luciferase units after normalization. (C) Reversibility of inhibitors was monitored by first incubating the
preadipocytes in differentiation medium containing 100 mg/ml SBM, 10 mM atRA, 10
22 mM 1,25(OH)2D3, or combinations of the three for 24 hrs (light
grey bars); the medium was then replaced with fresh, inhibitor-free medium (dark grey bars), and lipid content was measured as TG content per mg
protein. (D) SBM, unlike atRA and 1,25(OH)2D3, modulates mature adipocyte function. Mature adipocytes were treated with 100 mg/ml SBM, 10 mM
atRA, 10
-2 mM 1,25(OH)2D3, or combinations of the three for 24 hr, and lipid content was measured as TG content per mg protein. Data are expressed
as mean 6 SD. *P,0.01, **P,0.05 vs. controls. The results were verified by three repetitions of the experiments, which were each conducted in
triplicate.
doi:10.1371/journal.pone.0030831.g005
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ability to reduce Akt phosphorylation, may contribute to
repression of PPARc by SBM.
The cytokine TNF-a is also an important mediator of lipid
metabolism and also plays a role in inducing lipolysis [60]. TNF-a
can perturb the normal regulation of energy metabolism, and
enhanced TNF-a expression could be a cause as well as a
consequence of the decrease of lipidic depots in white adipose
tissue, the inhibition of insulin action, and the promotion of
apoptosis [61]. Therefore, we evaluated the lipolytic response to
SBM by measuring the expression levels of perilipin, HSL, and
TNF-a during adipocyte differentiation (Figure 4C). SBM
downregulated perilipin while upregulating TNF-a, but no
appreciable changes were observed for HSL expression. PPARc
is known to upregulate perilipin expression [62], whereas TNF-a is
known to promote phosphorylation and downregulation of
perilipin [63]. The TNF-a induction and PPARc repression
caused by SBM can explain why SBM treatment causes perlipin
downregulation. PPARc impact on glucose uptake, metabolism
and lipogenesis is well documented and as such its repression by
SBM may contribute to reduced lipogenesis while enhancing
lipolysis. TNF-a-induced lipolysis is also known to downregulate
anti-lipolytic genes PDE3B and Gia1, and our results were
consistent with the published reports [64,65]. TNFa leads to both
physiological apoptosis and lipolysis as is clearly evident from
target gene expression. Further while apoptosis is marked at
100 mg/ml SBM concentration, lipolysis is clearly evident at
concentration as low as 10 mg/ml, where no significant apoptosis
is observed suggesting that these are independent physiological
processes. However at higher concentration 50–100 mg/ml we
cannot rule out lipolysis due to cell death and such contributions
cannot be practically dissected. So far it is amply clear that SBM
effector functions in adipocytes leading to inhibition of adipogen-
esis and induction of apoptosis at higher concentration and
lipolysis even at concentration as low as 10 mg/ml are governed by
its ability to inhibit Akt while augmenting TNFa pathway. Also,
that these effects are dependent on its proteolytic activity. While it
is amply clear that SBM catalytic activity is required for inducing
these effects, intriguingly catalytically active papain (member
cyteine protease) failed to show significant effect. This suggest that
either this could be due to specificity in SBM catalysis or may have
structural contributions as well. SBM proteolytic actions on surface
receptors of immune cells have been addressed [25,27]. It remains
to be seen how SBM’s proteolytic activity is required for its role in
inhibiting adipocyte differentiation and if the above pathways
could be mechanistically linked.
SBM’s ability to modulate adipogenesis compared to natural
vitamins atRA and 1,25(OH)2D3 was evaluated, because these
vitamins have proven, mechanistically addressed roles in adipo-
genesis. SBM, unlike atRA and 1,25(OH)2D3, was able to inhibit
adipogenesis irreversibly, and it also modulated adipocyte function
post-differentiation (Figure 5C and D). atRA and 1,25(OH)2D3
reversibly inhibit adipocyte differentiation and, in the case of
atRA, only early in adipogenesis. They do not modulate the
function of mature adipocytes [21,66]. This could explain failure
of atRA to modulate CD36 promoter reporter activity and may be
implicated to absence of signaling effectors that mediate atRA
regulation of PPARc expression [66,67]. Treatment of adipocytes
with SBM and atRA together was more potent than treatment
with either of them alone or in other combinations. This result
could be due to complementation by atRA of SBM’s effects at the
level of MCE, which SBM does not modulate.
Many attempts have been made to correct the metabolic
disparity that is involved in obesity, using reagents such as
sibutramine (an appetite suppressor), orlistat (a gastrointestinal
lipid inhibitor), and fibrates (PPAR-a agonists) [68,69]. Adminis-
tration of these drugs, however, frequently causes undesirable side
effects such as a dry mouth, anorexia, constipation, insomnia,
dizziness, and nausea [70]. These negative effects have led to a
high demand for therapeutically potent, yet safe anti-obesity drugs.
SBM’s acceptability as an orally administered enzyme and
bioavailability with minimal side effects [24,30,31,32,33] have
been confirmed by several Good Clinical Practice (GCP)-
conforming clinical studies [26,33,34,35,36]. Our in vitro experi-
mental data indicate that SBM may be a potent modulator of
obesity by repressing the PPARc-regulated adipogenesis pathway
and augmenting the TNFa-induced lipolytic and apoptotic
pathway (Figure 6). This naturally occurring phytotherapeutic
may be beneficial for reducing diet-related obesity via its ability to
regulate adipocyte differentiation. Further evaluation by in vivo
experiments need to be done to support the therapeutic use of
SBM as an anti-obesity nutritional herbal supplement. It will be
interesting to examine whether the use of herbal formulations of
SBM other than anti-obesity pill (France Vita Natura Pvt Ltd.)
with quercitin, vinegar, hydroxyl citric acid (HCA), green tea, and
guggulipid extract can be extended for obesity disorder.
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Figure 6. Schematic of SBM modulation of adipogenesis and
adipocyte function. SBM blocks adipocyte differentiation and
promotes lipolysis and apoptosis in mature adipocytes by increasing
TNF-a expression and reducing Akt phosphorylation. While TNFa leads
to enhanced lipolysis, increased apoptosis, and repressed PPARc
expression, reducing Akt phosphorylation leads to only the latter two.
doi:10.1371/journal.pone.0030831.g006
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